山东未名生物医药股份有限公司 2025 年股票期权激励计划实施考核办法 山东未名生物医药股份有限公司 2025 年股票期权激励计划实施考核办法 为促进山东未名生物医药股份有限公司（简称"公司"）建立健全激励与约 束相结合的中长期激励机制，保证本次股票期权激励计划的顺利进行，进一步完 善公司法人治理结构，形成良好均衡的价值分配体系，激励公司经营管理决策层、 中高层管理人员和核心骨干人员努力开展工作，保证公司业绩稳步提升，确保公 司发展战略和经营目标的实现，根据国家有关规定和公司实际情况，特制定本办 法。 一、考核目的 为进一步完善公司治理结构，建立健全公司长期激励与约束机制，倡导公司 与管理层及骨干员工共同持续发展的理念，充分调动董事、高级管理人员、中层 管理人员及核心骨干员工的积极性，有效地将股东利益、公司利益和员工个人利 益结合在一起，提升公司的核心竞争力，确保公司发展战略和经营目标的实现， 本公司依据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司股 权激励管理办法》等有关法律、法规及规范性文件和《山东未名生物医药股份有 限公司章程》制定本计划。 二、考核原则 考核评价必须坚持公正、公开、公 ...

山东未名生物医药股份有限公司 董事会薪酬与考核委员会关于公司 2025 年股票期权 激励计划相关事项的核查意见 山东未名生物医药股份有限公司（以下简称"公司"）董事会薪酬与考核委 员会根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、《深圳证券交易所股票上市规则》（以下简称 "《上市规则》"）、《山东未名生物医药股份有限公司章程》（以下简称"《公 司章程》"）的规定，对《山东未名生物医药股份有限公司 2025 年股票期权激 励计划（草案）》（以下简称"本激励计划"）及其他相关资料进行审核，发表 核查意见如下： 一、公司不存在《管理办法》等法律、法规规定的禁止实施股权激励计划的 情形，包括： （二）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （三）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政 处罚或者采取市场禁入措施； （三）上市后最近 36 个月内出现过未按法律法规、《公司章程》、公开承 诺进行利润分配的情形； （四）法律法规规定不得实行股权激励的； （ ...

| 38 | 股东会审议股权激励计划草案时，关联股东是否拟 | 不适用 | | --- | --- | --- | | | 回避表决 | | | 39 | 是否不存在重大无先例事项 | 是 | | | 本公司保证所填写的情况真实、准确、完整、合法，并承担因所填写情况 | | | 有误产生的一切法律责任。 | | | | | | 2025年8月29日 | 山东未名生物医药股份有限公司 董事会 公司简称：ST未名 股票代码：002581 独立财务顾问：无 | 序 | 事项 | 是否存在 该事项（ | | | --- | --- | --- | --- | | 号 | | 是/否/不 适用） | 备注 | | | 上市公司合规性要求 | | | | 1 | 最近一个会计年度财务会计报告是否未被注册会计 | 是 | | | | 师出具否定意见或者无法表示意见的审计报告 | | | | 2 | 最近一个会计年度财务报告内部控制是否未被注册 | 是 | | | | 会计师出具否定意见或无法表示意见的审计报告 | | | | | 上市后最近36个月内是否未出现过未按法律法规、 | | | | 3 | 公司章程、公开承诺进行 ...

山东未名生物医药股份有限公司 2025 年股票期权激励计划激励对象名单 山东未名生物医药股份有限公司（以下简称"公司"或"本公司"）2025 年股票期权激励计划（以下简称"本激励计划"）拟授予的股票期权在各激励对 象间的分配情况如下： | 序号 | 姓名 | 职务 | 授予股票期权的 数量（万份） | 占本次授予股票期 权总数的比例 | 占本激励计划公 告时总股本的比 | | --- | --- | --- | --- | --- | --- | | | | | | | 例 | | 1 | 岳家霖 | 董事长、总经理 | 580.00 | 12.61% | 0.88% | | 2 | 徐隽雄 | 副董事长、副总经理 | 185.00 | 4.02% | 0.28% | | 3 | 周婷 | 董事、财务总监 | 126.25 | 2.74% | 0.19% | | 4 | 史晓如 | 董事、董事会秘书 | 125.55 | 2.73% | 0.19% | | 5 | 陈星 | 董事、副总经理 | 102.12 | 2.22% | 0.15% | | 6 | 黄桂源 | 董事 | 98.20 | 2.13% | ...

山东未名生物医药股份有限公司 2025 年股票期权激励计划（草案）摘要 证券代码：002581 证券简称：ST 未名 山东未名生物医药股份有限公司 2025 年股票期权激励计划 （草案）摘要 二零二五年八月 山东未名生物医药股份有限公司 2025 年股票期权激励计划（草案）摘要 声明 本公司及全体董事、高级管理人员承诺本激励计划及其摘要不存在虚假记载、 误导性陈述或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律 责任。 - 1 - 山东未名生物医药股份有限公司 2025 年股票期权激励计划（草案）摘要 特别提示 一、山东未名生物医药股份有限公司（以下简称"未名医药"或"本公司"、 "公司"）2025 年股票期权激励计划（以下简称"本激励计划"、"本计划"） 系依据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司股 权激励管理办法》（以下简称"《管理办法》"）及其他有关法律、法规及规范 性文件和《山东未名生物医药股份有限公司章程》制定。 二、本激励计划采取的激励形式为股票期权。股票来源为公司向激励对象定 向发行的本公司人民币 A 股普通股股票。 山东未名生物医药股份有限公司 2025 ...

浙江天册（深圳）律师事务所 关于 山东未名生物医药股份有限公司 2025 年股票期权激励计划（草案）的 法律意见书 1. 本法律意见书的出具已得到公司如下保证：公司向本所提供的文件资料 及所作出的陈述和说明均是真实、准确、完整和有效的，且一切足以影响本法律 意见书的事实和文件均已向本所披露，无任何隐瞒或重大遗漏；公司提供的文件 资料中的所有签字及印章均是真实的，文件的副本、复印件或传真件与原件相符。 2. 本所经办律师依据本法律意见书出具日以前已经发生或者已经存在的事 实和国家正式公布、实施的《公司法》《证券法》《管理办法》等有关规定，并 基于对有关事实的了解和对有关规定的理解发表法律意见。 二〇二五年八月 中国广东省深圳市南山区科发路 222 号康泰创新广场 34 层 518052 电话：0755-26907494 传真：0755-26906383 http://www.tclawfirm.com 法律意见书 致：山东未名生物医药股份有限公司 浙江天册（深圳）律师事务所（以下简称本所）受山东未名生物医药股份有 限公司（以下简称未名医药或公司）委托，担任公司本次实施 2025 年股票期权 激励计划（以下简称本 ...

Market Overview - The biopharmaceutical sector experienced a decline of 2.85% on August 27, with Kanghua Biotech leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Wuwei Biotech (300357) saw a significant increase of 5.38%, closing at 30.95 with a trading volume of 299,000 shares and a transaction value of 915 million yuan [1] - Kanghua Biotech (300841) reported a notable decline of 8.89%, closing at 76.60 with a trading volume of 125,200 shares and a transaction value of 993 million yuan [2] - Anke Biotech (300009) also faced a drop of 5.59%, closing at 11.14 with a trading volume of 862,300 shares and a transaction value of 990 million yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 1.853 billion yuan from institutional investors, while retail investors saw a net inflow of 1.543 billion yuan [2] - The capital flow for individual stocks indicates that Hualan Biotech (002007) had a net inflow of 32.28 million yuan from institutional investors, while it faced a net outflow of 40.67 million yuan from speculative funds [3] - The overall trend shows that retail investors are actively investing in the sector despite the institutional outflows [2][3]

Core Viewpoint - ST Unimed (002581) reported significant declines in revenue and net profit for the first half of 2025, indicating severe operational challenges and financial distress [1] Financial Performance Summary - Total revenue for the first half of 2025 was 70.77 million yuan, a decrease of 66.42% year-on-year [1] - Net profit attributable to shareholders was -67.30 million yuan, down 127.26% year-on-year [1] - Gross margin was 70.19%, a decline of 12.97% compared to the previous year [1] - Net margin was -124.57%, a drop of 958.12% year-on-year [1] - Total expenses (selling, administrative, and financial) accounted for 184.83% of revenue, an increase of 116.55% year-on-year [1] Cash Flow and Financial Ratios - Operating cash flow per share was -0.22 yuan, a decrease of 183.51% year-on-year [1] - The company’s return on invested capital (ROIC) over the past decade has been weak, with a median of 0.66% and a worst year in 2023 at -13.03% [2] - The average operating cash flow over the past three years relative to current liabilities was -55.08% [2] Operational Challenges - The significant drop in revenue and profit was attributed to the suspension of production and sales by subsidiaries [1] - The company has experienced five years of losses since its listing, indicating a history of financial instability [2] - The decline in financial expenses was due to reduced loan interest payments, but overall financial health remains concerning [1]

Core Viewpoint - The company announced the cancellation of unexercised stock options from the first exercise period of the 2023 stock option incentive plan, which has now expired, affecting a total of 16,617,396 stock options [4][6]. Summary by Sections 1. Approval Procedures and Plan Overview - The 2023 stock option incentive plan was approved by the board and relevant committees, with independent opinions provided by independent directors and legal opinions from Zhejiang Tianche Law Firm [1][2]. 2. Stock Option Grant and Conditions - The stock options were granted on May 29, 2023, with a total of 59 million options registered under the code 037368, and the exercise price set at 21.23 yuan per share [3][4]. 3. Cancellation of Stock Options - Due to 25 incentive targets leaving the company, 9,998,300 stock options were canceled. Additionally, 77 eligible incentive targets were allowed to exercise a total of 24,500,500 stock options [4][5]. 4. Impact of Cancellation - The cancellation of the stock options will not materially affect the company's financial status or operational results, nor will it impact the implementation of the 2024 equity incentive plan [6]. 5. Committee Opinions - The board's remuneration and assessment committee confirmed that the cancellation complies with relevant regulations and does not harm the interests of the company or its shareholders [6]. 6. Legal Opinions - Legal opinions confirmed that the company has fulfilled necessary approvals and disclosures regarding the cancellation of stock options, in accordance with applicable regulations [6].

Core Viewpoint - The report highlights significant declines in revenue and net profit for Shandong Sinobioway Biomedicine Co., Ltd. during the first half of 2025, primarily due to the suspension of production and sales at a key subsidiary, impacting overall financial performance [2][3][10]. Company Overview and Financial Indicators - Company name: Shandong Sinobioway Biomedicine Co., Ltd. - Stock code: 002581 - Total assets as of June 30, 2025: CNY 2,050,202,194.41, a decrease of 6.64% from the previous year [3][5]. - Revenue for the first half of 2025: CNY 70,771,540.88, down 66.42% from CNY 210,782,004.46 in the same period last year [5][6]. - Net profit attributable to shareholders: CNY -67,302,664.90, a decline of 127.26% compared to CNY -29,614,917.07 in the previous year [5][6]. - Basic and diluted earnings per share: CNY -0.1020, a decrease of 127.17% [3][5]. Main Business Analysis - The company operates in the pharmaceutical manufacturing sector, focusing on products such as nerve growth factors, interferons, and vaccines [3][5]. - The revenue breakdown shows that nerve growth factors accounted for 90.75% of total revenue, while interferons contributed only 9.21%, reflecting a significant drop of 95.41% compared to the previous year [5][6]. Risk and Response - The company faces risks related to new drug development, which is characterized by long cycles, high investment, and uncertainty in market approval [10][12]. - A key subsidiary, Tianjin Sinobioway, was suspended from production and sales due to regulatory issues, which is expected to have a significant impact on the company's operations [10][12]. - The company plans to enhance its research and development capabilities and optimize its product pipeline to mitigate risks associated with new drug development [10][12]. Management Discussion and Analysis - The company has established a nationwide sales network and a professional marketing team to enhance its market presence [3][5]. - The company is committed to improving its product quality management in response to stricter regulatory requirements [10][12]. - The report indicates a focus on innovation and collaboration with quality resources in the industry to expand its product offerings and market reach [10][12].